We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Green Tea and Tai Chi for Bone Health (GTP-TC-Bone)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00625391
Recruitment Status : Completed
First Posted : February 28, 2008
Results First Posted : August 18, 2014
Last Update Posted : August 18, 2014
Information provided by (Responsible Party):

February 26, 2008
February 28, 2008
December 5, 2012
August 18, 2014
August 18, 2014
February 2008
August 2009   (Final data collection date for primary outcome measure)
Change From Baseline (100%) in Ratio of Bone Formation Marker to Bone Resorption Marker [ Time Frame: 24 weeks ]
Bone formation biomarker: bone-specific alkaline phosphatase (BAP) Bone resorption biomarker: tartrate-resistant acid phosphatase (TRAP)
attrition rate, compliance [ Time Frame: 24 weeks ]
Complete list of historical versions of study NCT00625391 on ClinicalTrials.gov Archive Site
Oxidative Stress Damage Biomarker [ Time Frame: 24 weeks ]
Oxidative stress damage biomarker: urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) test
bone turnover biomarkers, oxidative stress damage biomarker, biomechanical response [ Time Frame: 24 weeks ]
Not Provided
Not Provided
Green Tea and Tai Chi for Bone Health
GTP and Tai Chi for Bone Health: a Pilot Study
Osteoporosis is a major health problem in postmenopausal women. Our long-term goal is to develop a new alternative treatment that include a dietary supplement (green tea extract) and a mind-body exercise (Tai Chi) for lessening bone loss in postmenopausal women with low bone mass. A combination of dietary supplement and moderate intensity exercise now becomes a new alternative treatment in reducing bone loss in postmenopausal women with low bone mass, due to the possible stronger effects of the combination than individual treatments. Objective: To test a CAM intervention including green tea polyphenol (GTP) and Tai Chi (TC) exercise for feasibility, and to quantitatively assess their individual and conjugate effects on postmenopausal women with osteopenia. Hypotheses: (1) 24 weeks of GTP supplement, TC exercise, and their combination will benefit bone remodeling as measured by bone biomarkers and muscle strength/physical function in postmenopausal women with osteopenia compared to those receiving placebo only, and (2) the changes in bone biomarkers associated with bone remodeling will be correlated with the changes in oxidative stress.
This is a 24-week, randomized, and placebo-controlled intervention trial to investigate the effects of green tea polyphenols (GTP) and Tai Chi (TC) on relevant primary and secondary endpoints in postmenopausal women with osteopenia. Women at least 2 years after menopause, with osteopenia, will be recruited primarily from local senior independent/assisted living facilities, municipal senior community centers, and obstetrics and gynecology clinics. After screening, qualified participants will be matched for age and will be randomly assigned to one of the four treatment groups: placebo, GTP, placebo+TC, and GTP+TC. During the 24-week intervention, all participants will be provided with calcium and vitamin D daily. The participants in the placebo group will receive medicinal starch for 24 weeks. The GTP participants will receive GTP for 24 weeks. The placebo+TC participants will receive both placebo and TC treatments for 24 weeks. The GTP+TC participants will receive both GTP and TC treatments for 24 weeks. Participants will receive the primary and secondary outcome measures at baseline, 4, 12, and 24 weeks. The primary outcome measures are concentrations of bone biomarkers. The secondary outcome measure is a biomarker of oxidative stress DNA damage. Additional secondary outcome is muscle strength/physical function. Investigators evaluating the endpoints will be blinded to intervention allocation.
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
  • Drug: Placebo
    500 mg medicinal starch pills daily
    Other Name: Placebo control group
  • Drug: Green Tea Polyphenols (GTP)
    500 mg green tea polyphenols daily
    Other Name: Green tea polyphenols group
  • Drug: Placebo+Tai Chi (TC)
    500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
    Other Name: Placebo plus tai chi exercise group
  • Drug: GTP+TC
    500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
    Other Name: Green tea polyphenols plus tai chi exercise group
  • Placebo Comparator: Placebo pill
    24 weeks of placebo.
    Intervention: Drug: Placebo
  • Active Comparator: Green Tea Polyphenols (GTP)
    24 weeks of green tea polyphenols
    Intervention: Drug: Green Tea Polyphenols (GTP)
  • Active Comparator: Placebo+Tai Chi (TC)
    24 weeks of placebo plus Tai Chi exercise.
    Intervention: Drug: Placebo+Tai Chi (TC)
  • Active Comparator: GTP+TC
    24 weeks of green tea polyphenols plus Tai Chi exercise.
    Intervention: Drug: GTP+TC

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
August 2009
August 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women at least 2 years after menopause (to ensure established postmenopausal status).
  • Sedentary at baseline.
  • Normal laboratory evaluation, thyroid function, hepatic function, renal function.
  • Osteopenia.

Exclusion Criteria:

  • History of scoliosis, severe osteoarthritis, etc., or other spinal disease that may result in anatomy unsuitable for accurate bone densitometry.
  • History of cancer with some exceptions.
  • History of metabolic bone disease.
  • Having used anabolic steroids, calcitonin, calcitriol, alfacalcidol, etc.
  • Fluoride treatment at a dose greater than 1 mg/day any time.
  • History of glucocorticoid treatment.
  • Any previous treatment with bisphosphonates.
  • Uncontrolled intercurrent illness such as symptomatic congestive heart failure, myocardial infarction or stroke, hypertension, or terminal illness.
  • Physical conditions that preclude participation of exercise intervention.
  • Cognitive impairment.
  • Depression.
  • History of malabsorption syndrome and uncontrolled diabetes mellitus.
Sexes Eligible for Study: Female
Child, Adult, Senior
Contact information is only displayed when the study is recruiting subjects
United States
R21AT003735-01A1( U.S. NIH Grant/Contract )
R21AT003735-01A1 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Leslie Shen, Texas Tech University Health Sciences Center
Texas Tech University Health Sciences Center
National Center for Complementary and Integrative Health (NCCIH)
Principal Investigator: Chwan-Li (Leslie) Shen, PhD Texas Tech University Health Sciences Center
Texas Tech University Health Sciences Center
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP